Anebulo Pharmaceuticals, Inc. reported three months ended March 31, 2024 results: net income Net loss ... was $1.7 million, or $(0.06) per share, EPS $(0.06) per share.
“today announced financial results for the three months ended March 31, 2024”
Anebulo Pharmaceuticals, Inc. — fact timeline
Source-grounded facts extracted from Anebulo Pharmaceuticals, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.